Icon

Alexion Pharmaceuticals Inc Stock Analysis and Price Target COMMON STOCK | Biotechnology | NSD

N/A

Average User
Rating

N/A

Average Analyst
Rating
stockTargetAdvisor

Very Bullish

Stock Target Advisor
Analysis

USD 182.50

0.00 (0.00)%

USD 40.34B

3.00

N/A

N/A

Icon

ALXN

Alexion Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 182.50
0.00 0

N/A

Average User
Rating

N/A

Average Analyst
Rating
stockTargetAdvisor

Very Bullish

Stock Target Advisor
Analysis

USD 40.34B

N/A

USD 182.50

Alexion Pharmaceuticals Inc Stock Forecast

N/A

Based on the Alexion Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Alexion Pharmaceuticals Inc is not available over the next 12 months. Alexion Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Alexion Pharmaceuticals Inc is Very Bullish, which is based on 2 positive signals and 0 negative signals. At the last closing, Alexion Pharmaceuticals Inc’s stock price was USD 182.50. Alexion Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Alexion Pharmaceuticals Inc
No recent average analyst rating found for Alexion Pharmaceuticals Inc

Company Overview

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generaliz...Read More

http://www.alexion.com

121 Seaport Boulevard, Boston, MA, United States, 02210

3,837

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

  • 1.26

  • N/A

  • 5.36

  • N/A

  • 9,803,110

  • USD 165.77

  • 8,553,633

  • USD 182.75

  • 0.27%

  • 4.44%

  • 88.02%

  • N/A

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Security Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Alexion Pharmaceuticals Inc (Sector: Biotechnology )

N/A

ETFs Containing ALXN

Symbol Name Weight Mer Price(Change) Market Cap
ETLI:F
Legal & General UCITS ETF.. 3.37 % 0.49 % -0.11 (-0.95%) USD0.04B
ETLI:XETRA
L&G Pharma Breakthrough U.. 3.37 % 0.49 % -0.10 (-0.93%) USD0.04B
BIOT:SW
L&G Pharma Breakthrough U.. 3.37 % 0.00 % -0.06 (-0.54%) N/A
2B70:F
iShares IV Public Limited.. 3.22 % 0.35 % +0.04 (+0.63%) USD0.46B
2B70:XETRA
iShares Nasdaq US Biotech.. 3.22 % 0.35 % -0.10 (-1.69%) USD0.46B
BTEC:SW
iShares Nasdaq US Biotech.. 3.22 % 0.00 % -0.01 (-0.11%) USD0.47B
BIS
ProShares UltraShort Nasd.. 3.02 % 0.95 % +0.06 (+0.33%) USD4.60M
ZBIO
ProShares UltraPro Short .. 3.02 % 0.95 % 0.00 (0.00%) USD2.51M
LABD
Direxion Daily S&P Biotec.. 0.00 % 1.00 % -0.37 (-2.68%) USD0.16B
UBIO
ProShares UltraPro Nasdaq.. 0.00 % 0.95 % 0.00 (0.00%) USD0.02B

Frequently Asked Questions About ALXN Stock

Stock Target Advisor's fundamental analysis for Alexion Pharmaceuticals Inc's stock is Very Bullish.

Unfortunately we do not have enough data on ALXN's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ALXN's stock to indicate what its average analyst target is.

ALXN stock's Price/Earning ratio is 59.23. Based on this ALXN may be a overvalued for its sector.

The last closing price of ALXN's stock was USD 182.50.

The most recent market capitalization for ALXN is USD 40.34B.

Unfortunately we do not have enough analyst data on ALXN's stock to indicate whether its price will go up or not.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...